American Century Companies Inc. reduced its position in Johnson & Johnson (NYSE:JNJ) by 10.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,437,375 shares of the company’s stock after selling 854,038 shares during the period. Johnson & Johnson comprises 1.0% of American Century Companies Inc.’s investment portfolio, making the stock its 10th biggest position. American Century Companies Inc. owned approximately 0.28% of Johnson & Johnson worth $1,039,150,000 at the end of the most recent reporting period.
Other institutional investors also recently added to or reduced their stakes in the company. Goodman Financial Corp purchased a new position in Johnson & Johnson during the fourth quarter worth $104,000. Price Wealth Management Inc. purchased a new position in Johnson & Johnson during the fourth quarter worth $148,000. Roble Belko & Company Inc increased its position in Johnson & Johnson by 59.7% during the fourth quarter. Roble Belko & Company Inc now owns 1,164 shares of the company’s stock worth $163,000 after buying an additional 435 shares in the last quarter. Cerebellum GP LLC purchased a new position in Johnson & Johnson during the fourth quarter worth $166,000. Finally, Legacy Advisors LLC purchased a new position in Johnson & Johnson during the third quarter worth $202,000. 67.40% of the stock is owned by institutional investors.
Several research firms have weighed in on JNJ. Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the stock a “hold” rating in a research report on Monday, January 22nd. BTIG Research reissued a “sell” rating and set a $110.00 price target on shares of Johnson & Johnson in a research report on Wednesday, January 24th. Stifel Nicolaus raised their price target on Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 price objective for the company in a research report on Tuesday, January 23rd. Finally, Citigroup lowered their price objective on Johnson & Johnson from $150.00 to $146.00 and set a “neutral” rating for the company in a research report on Tuesday, February 27th. Five equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company. Johnson & Johnson has an average rating of “Hold” and an average target price of $142.23.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 17th. The company reported $2.06 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.06. Johnson & Johnson had a return on equity of 30.65% and a net margin of 1.58%. The firm had revenue of $20.01 billion for the quarter, compared to analysts’ expectations of $19.50 billion. During the same quarter last year, the firm earned $1.83 earnings per share. The firm’s revenue for the quarter was up 12.6% compared to the same quarter last year. equities research analysts predict that Johnson & Johnson will post 8.13 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 12th. Investors of record on Tuesday, May 29th will be issued a $0.90 dividend. The ex-dividend date of this dividend is Friday, May 25th. This represents a $3.60 dividend on an annualized basis and a yield of 2.91%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.84. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.03%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.